Harm and benefits of short-term pre-operative radiotherapy in patients with resectable rectal carcinomas

被引:25
作者
Bakx, R
Emous, M
Legemate, DA
Zoetmulder, FAN
van Tienhoven, G
Bemelman, WA
van Lanschot, JJB
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Surg, NL-1105 AZ Amsterdam, Netherlands
[2] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg, Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands
来源
EJSO | 2006年 / 32卷 / 05期
关键词
rectal cancer; pre-operative radiotherapy; harm and benefits;
D O I
10.1016/j.ejso.2006.02.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To weigh the harms and benefits of short-term pre-operative radiotherapy in the treatment of resectable rectal cancer. Methods: The benefits (reduction of local recurrence) and harm (increase of short-term complications) of short-term pre-operative radiotherapy are balanced using a model which classifies patients in one of five outcome combinations; 1-benefit without additional harm, 2-benefit with additional harm, 3-no benefit, no additional harm, 4-no benefit but additional harm, 5-mortality due to combined treatment. The results of four randomised clinical trials (RCT) which study the addition of short-term pre-operative radiotherapy in rectal cancer were classified according to this model. Results: Five to thirteen percent of the patients have benefit without additional harm of pre-operative radiotherapy, while 0-2% have benefit with additional harm; 74-87% has neither benefit nor additional haem and 6-11% have no benefit but additional harm. A small percentage of patients (1-6%) dies post-operatively as a result of the addition of radiotherapy. Conclusion: This model provides a transparent appreciation of the harmful and beneficial effects of any treatment modality investigated by means of a randomised clinical trial. As for short-term pre-operative radiotherapy in resectable rectal cancer is shown, a small percentage of patients benefits from such treatment. Most patients have neither benefit nor additional harm, while a small percentage suffers from additional harm while not receiving any benefit. (C) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:520 / 526
页数:7
相关论文
共 29 条
[11]  
Gray R, 2001, LANCET, V358, P1291
[12]  
HEALD RJ, 1986, LANCET, V1, P1479
[13]   CONSENSUS METHODS FOR MEDICAL AND HEALTH-SERVICES RESEARCH [J].
JONES, J ;
HUNTER, D .
BRITISH MEDICAL JOURNAL, 1995, 311 (7001) :376-380
[14]   Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands [J].
Kapiteijn, E ;
Putter, H ;
van de Velde, CJH .
BRITISH JOURNAL OF SURGERY, 2002, 89 (09) :1142-1149
[15]   Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer [J].
Kapiteijn, E ;
Marijnen, CAM ;
Nagtegaal, ID ;
Putter, H ;
Steup, WH ;
Wiggers, T ;
Rutten, HJT ;
Pahlman, L ;
Glimelius, B ;
van Krieken, JHJM ;
Leer, JWH ;
van de Velde, CJH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (09) :638-646
[16]   MESORECTAL EXCISION FOR RECTAL-CANCER [J].
MACFARLANE, JK ;
RYALL, RDH ;
HEALD, RJ .
LANCET, 1993, 341 (8843) :457-460
[17]   Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure - Applications to highly cited trials in cardiovascular medicine [J].
Mancini, GBJ ;
Schulzer, M .
CIRCULATION, 1999, 99 (03) :377-383
[18]  
MARIJNEN CA, 2006, 2005 GASTR CANC S HO
[19]   Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: Report of a multicenter randomized trial [J].
Marijnen, CAM ;
Kapiteijn, E ;
van de Velde, CJH ;
Martijn, H ;
Steup, WH ;
Wiggers, T ;
Kranenbarg, EK ;
Leer, JWH .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :817-825
[20]  
Martling A, 2001, CANCER, V92, P896, DOI 10.1002/1097-0142(20010815)92:4<896::AID-CNCR1398>3.0.CO